(Q80274942)
Statements
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02 (English)
Richard K Valicenti
Michelle DeSilvio
Gerald E Hanks
Arthur Porter
Harmar Brereton
Seth A Rosenthal
William U Shipley
Howard M Sandler
Radiation Therapy Oncology Group Protocol 92-02
18 September 2006